Medicure Inc. (TSX: MPH)(AMEX: MCU), a cardiovascular-focused biopharmaceutical company, today announced that the positive results from the Phase II MATCHED study, which evaluated the combination of MC-1 and lisinopril in patients with coexisting type II diabetes and hypertension, will be presented today at the Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Annual Conference 2008 in Atlanta, GA.
Data presented from the poster titled, "MC-1 and Angiotension Converting Enzyme Therapeutic Combination for Hypertensive Diabetics (MATCHED): An Evaluation of Ambulatory Blood pressure and Metabolic Function", included previously released metabolic and cardiovascular results:
- The combination of MC-1 300mg and lisinopril 20mg had a reduction in fasting serum glucose of 1.45 mmol/L (p equals 0.026) versus placebo.
- In patients with elevated baseline triglycerides (greater than 1.7mmol/L), the combination of MC-1 300mg and lisinopril 20mg had a reduction of 0.7 mmol/L (p equals 0.040) versus baseline.
- In patients with elevated baseline LDL (greater than 2.6 mmol/L), the combination of MC-1 300mg and lisinopril 20mg had a reduction of 0.4 mmol/L (p equals 0.045) versus baseline.
- The combination of MC-1 300mg and lisinopril 20mg had a reduction in mean daytime ambulatory systolic blood pressure (MDASBP) of 12.0 mmHg (p less than 0.0001) from baseline after 8 weeks of therapy as compared to 7.5 mmHg with 20mg lisinopril monotherapy, equating to an additional 4.5 mmHg reduction (p equals 0.130).
- The combination of MC-1 300mg and lisinopril 20mg had a reduction in mean daytime ambulatory diastolic blood pressure (MDADBP) of 7.5 mmHg (p less than 0.0001) from baseline after 8 weeks of therapy as compared to a 4.1 mmHg reduction with 20mg lisinopril monotherapy, equating to an additional 3.4 mmHg reduction (p equals 0.060).
"The data from MATCHED demonstrate the potential for the chronic application of MC-1 in patients with metabolic and cardiovascular disease," commented Medicure's President and CEO, Albert D. Friesen, PhD. "We are currently working with our clinical and scientific advisors to develop an appropriate study design to further confirm MC-1's chronic application efficacy."
Medicure completed the Phase II MATCHED study (MC-1 and ACE Therapeutic Combination for Hypertensive Diabetics) in September 2005. MATCHED was a randomized, parallel group, cross-over, double-blind, placebo-controlled comparison of 100, 300 or 1000 mg of MC-1 alone and in combination with 20 mg of lisinopril. The study results are based on a population of 120 patients with coexisting type II diabetes and hypertension from 12 sites across Canada.
About Medicure Inc.
Medicure Inc.
